Fibrotic Diseases

Targeting Latent TGFβ1

TGFβ1 is a protein growth factor that plays a complex role in regulating the human immune system. Selectively inhibiting TGFβ1 can support treatment for many diseases related to the immune system, such as fibrosis.

TGFβ1 has historically proved to be a challenging target in drug development. Traditional approaches work by broadly inhibiting the signaling of multiple TGFβ forms (including TGFβ2 and TGFβ3), potentially resulting in unintended side effects and challenges to treatment. We believe our targeted approach of using highly selective growth factors can avoid these pitfalls.

We are currently developing a highly selective TGFβ1 investigational therapy for fibrosis.